Humira interchangeable biosimilars?

Short answer:
- In the US, some Humira (adalimumab) biosimilars are approved, but only some have an “interchangeable” designation. An interchangeable biosimilar can be substituted for Humira at the pharmacy (subject to state laws). Not all Humira biosimilars have this designation.

What that means in practice:
- Interchangeable = pharmacy-level substitution allowed in many states (with notification to the prescriber, and subject to state rules).
- Non-interchangeable biosimilars = substitutions typically require prescriber approval or patient-specific arrangements; you’d still get a biosimilar, but not automatically substituted.

Current status (US, as of the latest widely cited guidance):
- Cyltezo (adalimumab-adbm) has (or has had) FDA interchangeability designation with Humira. This means it can be substituted in states that allow it, without the prescriber’s explicit permission in many cases.
- Other adalimumab biosimilars (such as Amjevita and others) exist and are approved, but most have not carried FDA interchangeability designation.

Important caveats:
- Interchangeability is decided by the FDA and can change with new approvals. Always check the most current FDA Purple Book or FDA‑designated interchangeability list.
- State laws vary. Some states allow automatic substitution of an interchangeable biosimilar; others have stricter rules or require prescriber input.
- Even with interchangeability, you should involve your prescriber and pharmacist in any switch, and monitor for any changes in effect or side effects.

If you’d like, I can:
- Look up the very latest list of FDA-designated interchangeable adalimumab biosimilars and confirm which ones are currently interchangeable, or
- Provide country-specific information (for example, UK/EU substitution rules) if you’re asking about a location outside the US.

Tell me which country or the date you care about, and I’ll tailor the specifics.